{"entity":{"id":"claire-harrison","kind":"person","name":"Claire Harrison","aka":[],"tldr":"Led COMFORT-II, which established ruxolitinib as the first drug for myelofibrosis, and most UK MPN trials since.","summary":"Claire Harrison was principal investigator of COMFORT-II, the European trial showing the JAK inhibitor ruxolitinib shrinks spleens and improves symptoms compared with best available therapy in myelofibrosis, which with COMFORT-I made ruxolitinib the first approved MPN therapy. She has led the MAJIC, PT-1 and RESPONSE trials in polycythaemia vera and essential thrombocythaemia and chairs the UK MPN research network.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harrison%20CN%5BAuthor%5D%20myelofibrosis%20ruxolitinib"}],"tags":["mpn","jak-inhibitor","uk"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["guys-st-thomas"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012","paper-momentum-momelotinib-lancet-2023"],"journals":["blood"],"dependsOn":[],"notes":[],"role":"Professor of Myeloproliferative Neoplasms and Clinical Director of Haematology, Guy's and St Thomas' NHS Foundation Trust","institutionId":"guys-st-thomas","specialisms":["Myeloproliferative neoplasms","Myelofibrosis","JAK inhibitors","Clinical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harrison%20CN%5BAuthor%5D%20myelofibrosis%20ruxolitinib"}],"papers":[{"title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis (COMFORT-II)","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1110556"},{"title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide (MAJIC-ET)","journal":"Blood","year":2017,"doi":"10.1182/blood-2017-05-785790"},{"title":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1110557","doi":"10.1056/NEJMoa1110557"},{"title":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOMENTUM%20momelotinib%20danazol%20myelofibrosis%20anaemia%20Verstovsek%20Lancet%202023"}]},"route":"/people/claire-harrison/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"institution":[{"id":"guys-st-thomas","kind":"institution","name":"Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre","route":"/institutions/guys-st-thomas/"}],"paper":[{"id":"paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012","kind":"paper","name":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis","route":"/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/"},{"id":"paper-momentum-momelotinib-lancet-2023","kind":"paper","name":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor","route":"/key-papers/paper-momentum-momelotinib-lancet-2023/"}],"journal":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/"}]}}